Skip to main content
 

The Promise of Biosimilars

Wednesday, September 13, 2017

In 2010, the Biologics Price Competition and Innovation Act signed into law by President Barack Obama as part of the Affordable Care Act, aimed to promote the development of biological products and create competition, with the goals of increasing treatment options and reducing health care costs. On this episode, we are joined by Dr. Leah Christl who is the Associate Director for Therapeutic Biologics in the Office of New Drugs in the FDA's Center for Drug Evaluation and Research. Today, we are starting to see the fruits of that labor, there are several biosimilars on the market and more are under review for approval. In 2015, the U.S. Food and Drug Administration approved the first biosimilar product which happens to be a supportive treatment for cancer patients undergoing chemotherapy for acute myeloid leukemia.

Frankly Speaking About Cancer: Join host Kim Thiboldeaux, President and CEO of the Cancer Support Community, for a weekly radio broadcast empowering listeners to live well with cancer. Every Tuesday, 4PM ET (1PM PT)

Understanding Clinical Pathways

Tuesday, January 27, 2015

There are an estimated 14.5 million cancer survivors in the United States. By the year 2024, that number is expected to increase to about 19 million survivors, while the medical costs of cancer are projected to increase 39 percent by the year 2020. To help provide quality cancer care for these 19 million survivors, while also reining in the cost of care, the value of care patients receive must be considered. One of the main tools to help accomplish this is called a “clinical pathway.”

On this episode of Frankly Speaking About Cancer, Dr. Jennifer Malin joins guest host Linda House to explain clinical pathways

Frankly Speaking About Cancer: Join host Kim Thiboldeaux, President and CEO of the Cancer Support Community, for a weekly radio broadcast empowering listeners to live well with cancer. Every Tuesday, 4PM ET (1PM PT)